Copenhagen – The ScanBalt region, bundling a total of 24 biotech networks from Northern Europe, has published a report analyzing the economic potential of biotechnology and life sciences in the different ScanBalt regions. Using five groups of indicators such as R&D input, risk capital, human capital, biotech workforce and current impact the study gives an overview of the Scandinavian state of the art.
As a first result, the authors claim that all ScanBalt regions together are comparable to leading life science clusters in the US, especially regarding the number of graduates. Nevertheless, the study remarks that this potential is still far from being implemented in reality because the different clusters do not act as one and have different roles to play. As the report points out, the Danish-Norwegian ‘Medcoast’ Network and the Danish-Swedish ‘Medicon Valley’ network are the most developed, having scored ‘high’ in all indicators.
The German, Finnish, Estonian and Lithuanian biotech regions are classified as ‘co-location clusters’ with less risk capital, but high scores in the other indicators. The other regions were called “Scientific Fountains” with still low commercial impact. The report is available on the website of scanbalt: www.scanbalt.org